Evidence map›Paper›PMID 33409026›Full record

ArticleCureus2020

The Role of Vitamin C as Adjuvant Therapy in COVID-19.

Poona Kumari, Suman Dembra, Pariya Dembra, Fnu Bhawna, Ambresha Gul, Basma Ali, Hamza Sohail, Besham Kumar, Muhammad Khizar Memon, Amber Rizwan

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 15 pooled it
8.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 15 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Intravenous vitamin C use and risk of severity and mortality in COVID-19: A systematic review and meta-analysis.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2022
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Poona KumariInternal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
Suman DembraMedicine, Peoples University of Medical and Health Sciences for Women, Nawabshah, PAK.
Pariya DembraMedicine, Jinnah Sindh Medical University, Karachi, PAK.
Fnu BhawnaInternal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
Ambresha GulInternal Medicine, People's University of Medical and Health Sciences for Women, Nawabshah, PAK.
Basma AliInternal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
Hamza SohailInternal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
Besham KumarInternal Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.
Muhammad Khizar MemonInternal Medicine, Liaquat University of Medical and Health Sciences, Hyderabad, PAK.
Amber RizwanFamily Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.
National University of Medical Sciences · PKJinnah Postgraduate Medical Center · PKPeople’s University · INJinnah Sindh Medical University · PKSree Gokulam Medical College and Research Foundation · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective The anti-inflammatory properties of vitamin C (VC) and the promising results it has shown in the treatment for common cold have prompted clinicians to use it as adjuvant therapy in the treatment of COVID-19. The purpose of this study was to find out the role of VC as adjunctive therapy in coronavirus disease 2019 (COVID-19). Methodology This study was conducted from March to July 2020 in the COVID-19 unit of a tertiary care hospital in Karachi. In this randomized controlled trial (RCT), one group received the intervention [50 mg/kg/day of intravenous (IV) VC] along with the standard therapy, and the other group received standard therapy only. Data such as age, gender, vitals, and biochemical values as well as outcomes including the number of days required for treatment, hospital stay, need for ventilation, and mortality were compared between the two groups and recorded using a self-structured questionnaire. Results COVID-19 patients who received IV VC became symptom-free earlier (7.1 ± 1.8 vs. 9.6 ± 2.1 days, p-value: <0.0001) and spent fewer days in the hospital (8.1 ± 1.8 vs. 10.7 ± 2.2 days, p-value: <0.0001) compared to those who received standard therapy only. However, there was no significant difference in the need for mechanical ventilation (p-value: 0.406) and mortality (p-value: 0.31) between the two groups. Conclusion VC can significantly improve clinical symptoms in patients affected with COVID-19; however, it had no impact on mortality and the need for mechanical ventilation. More large-scale studies are required to further assess the role of VC in the treatment of COVID-19.

Indexed as

covid-19intravenous vitamin cpakistan

Identifiers

PMID33409026
PMCPMC7779177
OpenAlexW3106981969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.